Zantac Recall: FDA Recalls All Zantac & Ranitidine Products

On April 1, 2020, The Food and Drug Administration (FDA) requested the recall of all Zantac and ranitidine products from the U.S. market due to contamination with the probable human carcinogen N-Nitrosodimethylamine (NDMA).

Do I Have A Case?

Why Is The FDA Recalling All Zantac Products?

The FDA Zantac recall announcement acknowledges that NDMA impurities in the popular heartburn medications can increase to dangerous levels when the products are stored over time or exposed to higher temperatures. This determination echoes the findings reported to the FDA earlier this year by Emery Pharma, which found steady increases of NDMA production in Zantac and ranitidine products stored just above room temperature. Emery’s study also produced levels of NDMA exceeding the FDA’s daily acceptable intake limit of 96 nanograms in ranitidine products stored in temperatures as low as 158 degrees Fahrenheit for as little as five days.

Emery submitted these findings to the FDA in a Citizen Petition on January 2, 2020 and recommended the agency recall all Zantac and ranitidine products from the market. Additional testing has since found that older ranitidine products contained greater levels of NDMA, suggesting that NDMA levels in the drugs can increase over time.

Is This The First Zantac Recall?

No. The FDA has announced 16 different recalls of Zantac and ranitidine products since tests began discovering NDMA in the heartburn medications in September 2019. Until now, the agency had refrained from withdrawing all Zantac and ranitidine products from the market due to inconsistencies in NDMA levels found in previous tests. However, the FDA has now concluded that it can no longer guarantee the safety of the products due to unknowns about duration and conditions in which the drugs have been stored.

What Should I Do If I Am Currently Taking Zantac?

The FDA is recommending users of over-the-counter Zantac and ranitidine products to cease use immediately and safely dispose of any remaining medication. The agency advises patients taking prescription ranitidine products to speak with their healthcare provider to discuss alternative treatment options.

What Is NDMA and Why Is It Dangerous?

NDMA is considered a probable human carcinogen by multiple global health organizations. It was previously used to make rocket fuel, however, this was stopped after unusually high levels of the compound were found in the air, water, and soil samples collected near a rocket fuel manufacturing plant. NDMA is now only intentionally produced in the U.S. for research purposes.

Human exposure to unsafe levels of NDMA in Zantac and ranitidine products has been linked to the following cancers:

  • Bladder Cancer
  • Stomach Cancer
  • Intestinal Cancer
  • Colon/Colorectal Cancer
  • Liver Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Leukemia
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma

How We Can Help

GoldenbergLaw is currently representing clients who have been diagnosed with cancer after taking Zantac or ranitidine products. The Zantac Recall Attorneys at GoldenbergLaw have over 30 years of experience delivering justice to victims of corporate negligence. If you are interested in learning more about a Zantac recall lawsuit, contact us today for a free consultation. Let us delivery the Gold standard advocacy you deserve.

FDA Recalls Belviq Due To Cancer Risks

On February 13, 2020, the Food and Drug Administration (FDA) requested a recall of the prescription weight loss medications Belviq (lorcaserin) and Belviq XR after a study associated long term use with certain cancers. Belviq’s manufacturer, the Japanese pharmaceutical company Eisai Inc., voluntarily recalled the drug in response to the FDA’s recommendation.

What Is Belviq?

Belviq was approved by the FDA in 2012 as a prescription weight management treatment. It is approved for use for adults who have a body mass index (BMI) of over 30 or adults who have a BMI of 27 or more and have additional health risks.

What Did The FDA Study Find?

Shortly after Belviq was approved, the FDA authorized a clinical study to analyze cardiovascular problems associated with the drug. The double blind, placebo-controlled study involved 12,000 patients over a five year period and found occurrences of certain types of cancer in 7.7 percent of patients taking Belviq. This compares to occurrences of cancer in just 7.1 percent of patients taking a placebo. The study found more incidences of cancer among patients taking Belviq over a longer period of time.

What Cancers Is Belviq Linked To?

Patients taking Belviq developed a range of cancers, but the most common cancers reported included:

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer

Why Did The FDA Recall Belviq?

The FDA initially issued a Drug Safety Communication in January 2020 warning the public of a possible link between Belviq and increased cancer risks. Less than a month later, the agency issued an updated Drug Safety Communication recommending that Eisai Inc. recall Belviq from the U.S. market. The agency concluded that “the risks of lorcaserin outweigh its benefits” after its review of the clinical study.

How GoldenbergLaw Can Help

GoldenbergLaw is currently handling cases where an individual has taken Belviq and developed lung cancer, pancreatic cancer, or colorectal cancer. Contact us today for a free Belviq cancer lawsuit evaluation. Our Minnesota Cancer Attorneys have been litigating complex cancer cases for over three decades, let us deliver the Gold standard advocacy you deserve.

Juul Is Officially Not Cool

All PR is good PR, unless you’re Juul right now. With appearances across international news broadcasts, popular YouTubers’ channels and even on TikTok (the newest social media platform loved by teens), the perils of Juul have become widespread knowledge, exposing the company’s unethical development practices and marketing tactics. 

A recent Reuters investigation concluded that the company has been entrenched in controversial developments from its early stages. A former employee has disclosed that discussions around the product’s potency and addictiveness were debated initially, however any employee concerns about product safety took a backseat to the company’s exponential growth. What’s become clear is the true effects of Juul are surfacing through numerous studies investigating the potency and addictiveness of the product, particularly amongst teenage users. 

Juul Delivers More Nicotine than Most Cigarettes

In a new study out of Penn State University College of Medicine, researchers analyzed blood samples from six Juul users who were asked to puff on their device every 20 seconds for 10 minutes (a total of 30 puffs). “The Juul users we studied obtained blood nicotine concentrations almost three times as high as most of the e-cigarette users we previously studied,” said Jessica Yingst, a research project manager. 

When the research participants were also asked to rate their withdrawal symptoms and other effects like ni

cotine craving and anxiety before and after vaping, they reported higher levels of nicotine dependence than more than 3,000 long-term users of other e-cigarettes. “In previous studies, we found that e-cigarette users were less addicted than smokers. However, the high nicotine delivery of the product and the scores on this study suggest that Juul is probably as addictive as 

cigarettes,” said study co-author Jonathan Foulds, a professor of public health sciences.

Following this, according to interviews with over a dozen tobacco researchers, pediatricians and Reuters review of Juul patents and nicotine chemistry, “the breakthrough “nicotine salts” formula that made the Juul e-cigarette so addictive – and ignited the company’s explosive market-share growth – made Juul especially attractive to teenagers and other new users who otherwise would never have smoked cigarettes. 

Teens Seduced by Smooth Flavors and ‘Smoke Rings’

CDC research reveals two thirds of teens weren’t even aware Juul contained nicotine 

With the latest figures showing that two thirds of Juul users aged 15-24 didn’t always know that Juul contained nicotine, it’s no wonder why there’s concern around youth addiction and vaping-related illnesses, especially as young users continue to post photos or videos of themselves performing smoke stunts or smoking multiple Juul’s on social media, often tagged under the hashtags such as #juullife or #doit4juul. 

In the latest available data from the CDC in September 2019, it shows that more than one in four high schoolers – 27.5% – reported using e-cigarettes in the previous month, a figure that’s consistently kept climbing month after month, despite the growing public concern about the product. 

In an effort to try and curb youth addiction and usage, Juul recently stopped selling its best-selling Mint flavored pods at the beginning of November. The company’s surprise announcement came just weeks after it pulled the popular Mango, Creme, Fruit and Cucumber flavors from the shelves in October. 

Juul now only sells its Menthol, Classic Tobacco and Virginia Tobacco varieties, but there’s still cause for concern that teens will shift from Mint to Menthol. Studies published in the medical journal JAMA found that nearly 60% of high school students who vape use Juul, and mint was the most popular flavor among US 10th and 12th graders.

The Repercussions of a Youth Epidemic 

Vaping death toll hits 42, with 2,100+ cases reported nationwide 

Sadly, with the latest figures from the CDC revealing that 42 deaths and 2,172 vaping-related injury cases have been reported in addition to figures of American youths  addicted to nicotine reportedly reaching more than 5 million, it is clear this is an epidemic that is not going away any time soon.

If you or a loved one has been affected by Juul addiction or injury, we’re here for you. 

We are currently investigating cases where an individual has used JUUL for at least three months and developed:

Lung Injuries 

Heart Injuries 

Addiction

Alternative Injuries

Or has had a stroke or seizure

Do I Have a Case?  

If you or a loved one has been diagnosed with a severe lung disease such as Bronchioloitis Obliterans or pneumonia, suffered a heart attack, seizure, or stroke, or developed a nicotine addiction after the use of a JUUL e-cigarette product, please reach out to the Minnesota e-cigarette lawyers at GoldenbergLaw.  We will guide you through the legal process and fight to get you fair compensation. GoldenbergLaw delivers the gold standard advocacy you deserve.